Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics has entered into a definitive agreement with ProGen for the co-development and commercialization of RT-114, an oral Ranipill capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for obesity. The agreement includes a 50/50 cost and revenue share arrangement, with Rani leading development in the US, Europe, Canada, and Australia, and ProGen leading in the rest of the world. Phase 1 program is expected to initiate in 2025.
June 24, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rani Therapeutics has entered into a partnership with ProGen to co-develop and commercialize RT-114, an oral capsule for obesity. Rani will lead development in key markets including the US and Europe, with Phase 1 expected to start in 2025.
The partnership with ProGen and the exclusive rights to lead development in major markets like the US and Europe are positive indicators for Rani Therapeutics. The initiation of Phase 1 in 2025 suggests a clear development timeline, which is likely to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100